T.O. Boulevard revamp hinges on key project
Champions of the Thousand Oaks Boulevard Specific Plan are feverishly optimistic in their expectations for the future of the three-mile-long, mostly commercial corridor. But some remaining constraints are putting all eyes on the fate of one particular project — developer Rick Principe’s 53-unit mixed-use concept at 1850 Thousand Oaks Blvd.
Teledyne to raise $125M in debt sale
Thousand Oaks-based industrial conglomerate Teledyne Technologies hopes to raise up to $125 million in operating capital by selling debt. The company said that on Dec. 4 it will issue $30 million of senior unsecured notes at 2.6 percent due Dec. 4, 2019 and $95 million of 3.1 percent senior unsecured notes due on Dec. 6, Read More →
CLU rolls out Huddle to incubate startups in Westlake Village
California Lutheran University’s new Westlake Village co-working and teaching space, Huddle, is up and running with a slate of fall events that organizers hope will make it a hub for entrepreneurship in East Ventura County
Editorial: Happy birthday, Camarillo and Thousand Oaks
We’d be remiss if we did not take the opportunity to make note of the 50th anniversaries of two important communities in our region. Camarillo and Thousand Oaks both mark their golden anniversaries in 2014 and, all fanfare aside, it is noteworthy that both have made significant economic impacts on our region. Thousand Oaks presents Read More →
Teledyne to buy offshore oil equipment maker for $171M
Thousand Oaks-based industrial conglomerate Teledyne Technologies is buying Bolt Technology Corp., a maker of offshore oil exploration equipment, in an all-cash deal valued at $171 million. Teledyne said Sept. 3 that it will pay $22 per share to buy the Connecticut manufacturer. Bolt makes and supplies marine seismic energy products and replacement parts for offshore Read More →
Atara Biotherapeutics angles for $92M, but jobs are scarce
Atara is among a new breed of “virtual” biotech startups. Such firms operate with barebones staff and outsource research and manufacturing operations to contract organizations. They are becoming increasingly common as investors seek to mitigate the huge risks of bringing drugs to market, a process that can cost as much as $1.8 billion, according to industry estimates.
